{Reference Type}: Case Reports
{Title}: Global influence of dupilumab on Quality of Life in a severe asthma patient with T2 multimorbidities: a case report on atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.
{Author}: Colque-Bayona M;Hernández-Cano N;Tomás-Pérez M;Caballero T;Quirce S;Domínguez-Ortega J;
{Journal}: J Asthma
{Volume}: 61
{Issue}: 7
{Year}: 2024 Jul 28
暂无{DOI}: 10.1080/02770903.2023.2300712
{Abstract}: <B>UNASSIGNED: </B>Interleukin (IL)-4 and IL-13 are considered key drivers of type 2 inflammatory diseases. Dupilumab is a fully human monoclonal antibody that blocks the shared receptor component for IL-4 and IL-13, thus inhibiting signaling of both cytokines.<BR><B>UNASSIGNED: </B>We report a case of a patient with uncontrolled severe asthma and other T2 inflammatory diseases (atopic dermatitis, chronic rhinosinusitis with nasal polyposis and eosinophilic esophagitis) treated with dupilumab.<BR><B>UNASSIGNED: </B>After one year of treatment, dupilumab improved asthma control together with lung function parameters and airway inflammation. Additionally, a positive impact on quality of life (QoL), evaluated by validated questionnaires, across all the diseases was observed.<BR><B>UNASSIGNED: </B>In this case report, a positive and objectively measurable of global improvement on QoL across all four T2 comorbidities was observed after treatment with dupilumab, demonstrating the important role of IL-4 and IL-13 and the existence of a unifying pathological mechanism in T2 diseases.